Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$21.10M$21.10M+1,572.1% vs Q1 2025 Net Income-$1.04M-$1.04MN/M vs Q1 2025 EPS Diluted$0.00$0.00N/M vs Q1 2025 Operating Income-$996,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Margins · derivedOperating margin-4.7%+2030.1 pt vs Q1 2025
Net margin-4.9%+1999.4 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end